Normoglucemic men with intermittent claudication (n=41), mean age of 63 years, and sex-, age-, body mass index-, and smoking habit-matched controls (n=75) were compared for plasma lipoprotein and hemostatic variables. The patients had significantly lower levels of large high-density lipoprotein (HDL) particles (HDL a , HDL^, and HDLjJ and elevated lipoprotein (a) [Lp(a)] concentrations than the control subjects. Of the hemostatic variables, plasminogen activator inhibitor-1 (PAI-1), plasma antiplasmin, plasma fibrinogen, and urine /J-thromboglobulin concentrations were significantly elevated in patients. In intermittent claudication patients Lp(a) correlated significantly with activation of the coagulation system, ie, with the levels of plasma fibrinogen and urine fibrinopeptide A. No correlations between the values for Lp(a) and PAI-1 or plasma a^-antiplasmin were seen. The PAI-1 activity showed significant univariate correlations to the levels of HDL 3k , HDL^ (inverse), and very-low-density lipoprotein triglycerides, of which the positive correlation to HDL},, persisted in multivariate analysis ( r -M , P<.001). Independent characteristics for intermittent claudication estimated by multiple regression analysis were PAI-1, plasma fibrinogen, and HDL,., with a combined R 1 of 36. The intermittent claudication subgroup that was being treated with /3-blockers/thiazides had a higher frequency of coronary heart disease compared with the other patients. In addition, the patients taking 0-blockers/ thiazides had elevated triglyceride concentrations, lower HDL cholesterol with a size shift toward smaller particles, and a tendency toward raised PAI-1 and plasma a,-antiplasmin levels compared with the patient group that did not take these medications. (Arterioscler Thromb. 1993;13:1441-1448 KEY WORDS • intermittent claudication • lipoproteins • hemostasis function • triglyceride • HDL particle size subclasses • plasma flbrinogen • plasminogen activator inhibitor-1
P ronounced arteriosclerosis of the lower part of the aorta, the iliac arteries, and the arteries of the lower limbs affects walking capacity, leads to intermittent claudication, and may eventually lead to gangrene of the limb. Subjects with intermittent claudication also have an increased incidence of coronary heart disease (CHD) and cerebrovascular disease. A number of risk factors for intermittent claudication have been suggested, of which cigarette smoking and diabetes mellitus have been shown to be of the greatest importance. 34 The roles of hypertension and serum lipoproteins in the genesis of intermittent claudication are less convincing than in the development of CHD. 5 -6 But low concentrations of high-density lipoprotein cholesterol (HDL-C) have been shown to be a risk factor for intermittent claudication. 1 
5-
7 Two recent studies indicate that the inverse relation of HDL to atherosclerotic disease in the coronary arteries is accounted for by low levels of the largest HDL particles. 89 Whether such a relation also applies to peripheral atherosclerosis, ie, intermittent claudication, has not been reported.
An imbalance of the hemostatic systems also appears to be associated with intermittent claudication. Plasma fibrinogen concentration is increased in patients with intermittent claudication. 10 A continuous intravascular deposition of fibrin in vivo counterbalanced by an incessant fibrinolytic process is likely. Recent studies suggest that this balance is affected by lipoproteins, particularly the triglyceride-rich ones. 11 -12 In the present study lipoproteins and hemostatic variables were analyzed in patients with intermittent claudication. Our objective was twofold: first, to elucidate possible links between hemostatic function and lipoprotein metabolism, and second, to evaluate the explanatory power for intermittent claudication of both hemostasis and lipoprotein variables.
Methods

Patients
Forty-one normoglucemic men 63 ±4 (mean±SD) years of age who had been consecutively referred to the peripheral vascular unit at Karolinska Hospital during 1989 through 1990 because of clinical symptoms of intermittent claudication participated in the study. Patients and control subjects (vide infra) were informed about the study and their consent was obtained. Patients with rest pain or ulcers were excluded. None of the patients were taking lipid-lowering medication, and no major medical event had occurred during the 6 months before referral. All participants were examined by the same physician (Dr J. Johansson). The clinical characteristics of the subjects were evaluated by a structured interview protocol. A Swedish translation of Rose's questionnaire for intermittent claudication and angina pectoris was used. 13 Sixteen patients had hypertension and 8 had angina pectoris. A history of myocardial infarction was present in 3 patients and coronary bypass surgery had been performed on 3 subjects. Six patients took selective and 6 took nonselective /3-blockers. Four patients took thiazide diuretics, two of whom were also on /3-blockers. Another 10 patients regularly took some type of medication. Only 13 patients were free from hypertension or CHD and did not take regular medication. Of the 14 patients who took )3-blockers/thiazides, 8 had hypertension, 3 had angina pectoris, 2 had survived a myocardial infarction, and another 2 had been treated for angina pectoris with bypass surgery. The clinical diagnosis of patients and control subjects was confirmed by pulse plethysmography of the first toe from both sides and distal blood pressure measurements. 14 
Selection of Control Subjects
To every index patient an age-and sex-matched control subject was randomly chosen from the Stockholm County population. To avoid the possibly confounding influences of smoking and obesity on the concentrations of the measured lipoprotein and hemostasis variables, the index patients were also matched with a second control group not only for sex and age but also for smoking and body mass index (BMI; kg/m*). For each of the 41 patients, 10 men, born the same day as the patient, were randomly chosen from the population register (L-data) after exclusion of subjects with a history of hospital treatment during the last 5 years or presence of chronic disease including diabetes mellitus. A questionnaire inquiring about smoking habits, height, weight, status of health, and regular use of medication was sent to each of these 10 men. Mean response rate was 7 men (maximum, 10; minimum, 4). One of the men was randomly matched to the index patient to represent a "normal" subject in the general population, ie, matched only for age and sex. From the same original group a case-control subject for the index patient was picked by matching not only for sex and age but also for smoking habits and BMI. By this procedure 7 of the 41 randomly chosen normal subjects became identical with 7 of the selected control subjects. Lipoprotein analysis (see below) was done on all included subjects except for the lipoprotein(a) [Lp(a)] analysis, which was done on frozen serum from the last 27 patients and their sex-, age-, smoking habit-, and BMI-matched case-control subjects. Tests on hemostasis were consecutively and randomly performed in a subsample (33 control subjects and 24 patients).
Lipoproteins
Venous blood was drawn from the patients between 8 and 9 AM after fasting overnight. HDL particle size subclass analysis was performed on ice-cooled plasma by a combination of ultracentrifuge isolation of the total HDL fraction followed by separation on gradient gel electrophoresis as previously described.
1516 Particle diameter (4>) ranges for the HDL subclasses were defined as follows: HDL 2b , 9.71<0<12.9O n o ; HDL 2 Serum lipoproteins were analyzed on serum with Na 2 EDTA and merthiolate added for final concentrations of 1.3 mmol/L and 0.25 mmol/L, respectively. Very-low-density lipoproteins (VLDLs), low-density lipoproteins (LDLs), and HDLs were separated by a combination of ultracentrifugal and precipitation techniques as previously described, 17 and cholesterol 18 and triglyceride 19 concentrations were determined in serum and in each of the VLDL, LDL, and HDL fractions.
Lp(a) analysis was performed in one run on serum that had been stored at -70°C by using a commercial immunoradiometric assay (Pharmacia, Uppsala, Sweden).
Hemostatic Variables
Nine parts venous blood was drawn into one part trisodium citrate solution, 0.129 mol/L. Blood for determination of /3-thromboglobulin and fibrinopeptide A was anticoagulated according to the following references. Fibrinogen determinations were performed by a polymerization rate assay. 20 Fibrinopeptide A was determined in plasma and in urine by means of a radioimmunoassay 21 using reagents from IMCO, Stockholm, Sweden. The plasminogen activator inhibitor-1 (PAI-1) activity was determined by a functional spectrophotometric method 22 by using a kit from Biopool AB, UrneS, Sweden. a 2 -Antiplasmin was determined with a spectrophotometric assay 23 by using kits from KabiPharmacia, Stockholm, Sweden. Thrombin-antithrombin complex was determined by an enzyme-linked immunosorbent assay 24 (ELISA) kit (Enzymdiagnos TAT Micro; Behringwerke AG, Marburg, FRG). /3-Thromboglobulin in urine was determined by using a modification of a commercially available kit (Amersham, UK). The labeled antigen and the antiserum were diluted five times, von Willebrand factor antigen was determined by means of a commercial ELISA 25 (Asserachrom vWF, Diagnostica Stago, Asnieres, France). Protein C was determined by a functional amidolytic assay 26 (Coamate, Protein C, Chromogenix AB, Molndal, Sweden). Orosomucoid was determined by a routine nephelometric immunochemical assay.
Statistics
All statistical calculations were performed with a statistical computer program (STATGRAPHICS, Statistical Graphics Corporation, Inc, Rockville, Md). Mean values and standard deviations were calculated by conventional analysis. Individual values of skewed variables were fitted by logarithm to near-normal distribution. An unpaired Student's / test was used for group comparisons. Univariate correlations were calculated with the Spearman rank test and multivariate correlations by partial correlation analysis. In the multiple stepwise regression analysis the variable with the highest partial correlation coefficient was entered at each step until no variable remained with a probability value of less than .05.
Results
Matching of Controls
To our surprise, the smoking habits and the BMI of the randomly chosen normals and the selected smoking habit-and BMI-matched case-control subjects turned out to be virtually identical. The clinical characteristics given in Table 1 were insignificantly different between the normal subjects and the case-control subjects. BMI indicates body mass index; cigarette-years. As determined by control subjects.
Control
Subjects (n=75)
63 (4) 26 (3) 29 (39) 659 (386) 154 (20) 86 (8) 5.4(1.2) 149 (10) 231 (53) All (n=41) 63 (4) 26 (2) 18 (44) 770 (289) 160 (17) 87 (8) 5.5 (0. 6) 149 (14) 228 ( 64 (5) 26 (2) 14 (44) 806 (265) 160 (19) 86 (7) 5.4 (0. 7) 150 (14) 221 (48) With 0-Blockere/Thlazldes (n=14)
62 (5) 26 (3) 6 (43) 702 (334) 159 (13) 87 (8) 5.7 (0.6)
149 (16) 245 (90) are given as mean (SD) except for accumulated no significant differences between patients and
Hence, we combined the two groups into a single group comprising all 75 control subjects ( Table 1 ). The indicated variables in Table 1 showed practically the same values for both the patients taking /3-blockers/thiazides and those who did not take these agents. In the subsample in which hemostatic tests were performed, the clinical and laboratory characteristics given in Table 1 were insignificantly different between patients and control subjects except for the prevalence of current smokers. Twelve of 24 (50%) smoked in the patient group compared with 11 of 33 (33%) in the control group. No significant difference in clinical characteristics was seen between the 27 patients and the 27 matched casecontrol subjects who had Lp(a) analysis performed.
Lipoproteins
Cholesterol and triglycerides in the major lipoprotein fractions. Patients with intermittent claudication had higher serum triglyceride levels and higher VLDL cholesterol and VLDL triglyceride concentrations than control subjects, which was accounted for by the /3-blocker/thiazide-treated patient subgroup. This subgroup also showed a lower HDL-C concentration and a higher total cholesterol value ( Table 2) .
Lp(a). The Lp(a) concentration was significantly higher for patients, mostly as a result of the elevated levels in the /3-blocker/thiazide-treated subgroup. The Lp(a) concentration was correlated to plasma fibrinogen in patients (r=.46, P<.05) but not in control subjects. The urine fibrinopeptide A level was also positively correlated with the Lp(a) concentration (r=.41, P<.05), but no clear correlation for patients could be established because we had only seven observations of both variables in the patient group. No significant correlations between Lp(a) and variables describing fibrinolytic capacity, ie, PAI-1 and plasma a 2 -antiplasmin, were found for either patients or controls.
HDL subclass concentrations. The total HDL protein level was decreased in patients with intermittent claudication compared with control subjects because of significantly lower patient concentrations of the three subclasses containing the largest HDL particles, ie, HDLa, HDLz,, and HDLj, ( Table 3 ). The £-blocker/ thiazide-treated patient subgroup had elevated HDLJI, and decreased HDLa, levels compared with both the other patients and control subjects.
Hemostatic Variables
Because of the unbalanced prevalence of current smokers in the control and patient groups, for the data on which analyses were performed on hemostatic variables the two groups were divided into smokers and nonsmokers, and the concentrations of the tested variables were compared. Of the hemostatic variables, only the plasma fibrinogen concentration in the control group differed significantly between smokers and nonsmokers (3.48 g/L and 2.91 g/L, respectively; P<.01). For the patients, the corresponding values were 4.01 g/L for smokers and 3.58 g/L for nonsmokers (not significant [NS]).
Platelets. Platelet counts were the same for both patients and control subjects. The urinary excretion of £-thromboglobulin-like material, a marker for in vivo platelet activation, was significantly higher in patients (Table 4) , which was mostly accounted for by the patients not treated with /3-blockers/thiazides.
Coagulation system activation. The plasma fibrinogen concentration was significantly higher in the patient group than in the control group (Table 4) . The von Willebrand factor and protein C levels were the same in both groups. No group differences for the fibrinopeptide A concentration in plasma or urine were found. The thrombin-antithrombin complex levels were not significantly different between patients and control subjects, though there was a tendency toward higher values in the patients.
Fibrinolytic variables. The PAI-1 and a 2 -antiplasmin values were significantly higher in patients, indicating an impaired fibrinolytic capacity (Table 4) . These elevations were mainly accounted for by the /3-blocker/ thiazide subgroup. 
Characteristics of Patients With Intermittent Claudication
Multiple stepwise regression analysis, with intermittent claudication as the dependent variable and VLDL triglycerides, LDL cholesterol (LDL-C), HDL a , HDLj,, HDL a , PAI-1 activity, plasma fibrinogen, and plasma a 2 -antiplasmin as independent variables, showed that 36% (adjusted R 2 =36) of the intermittent claudication cases could be explained by PAI-1, plasma fibrinogen, and HDLj,. Their independent contributions (adjusted R 2 ) were .20, .11, and .05, respectively. The corresponding values, ie, from the group that included only patients not treated with 0-blockers and/or thiazides, were .20, .07, and .06, respectively.
Relations Between Various Lipoproteins and Hemostatic Function Variables
The concentrations of VLDL triglycerides, LDL-C, H D L a , and HDL^ were chosen to represent VLDL, LDL, and large and small HDL particles, respectively, and correlated to PAI-1 activity, plasma fibrinogen, and plasma orosomucoid levels (Table 5) . .6) (n=11) 20 (14) 1.08(0.14) Univariate analysis (Table 5) showed a highly significant positive correlation between the HDl^, level and PAI-1 activity. In contrast, the HDL a , concentration and PAI-1 were significantly negatively correlated. The values for HDI^, and HDLa, also showed positive and negative correlations, respectively, to VLDLs. The level of VLDL triglycerides and PAI-1 activity were positively correlated. Plasma fibrinogen concentration and plasma orosomucoid were highly significantly positively correlated. LDL-C was not correlated to any of these variables (not shown).
In partial correlation analysis (Table 5) , HDLo,, and PAI-1 remained highly significantly correlated when the concentrations of VLDL triglycerides, H D L a , and plasma fibrinogen were included in the model. Under similar conditions, HDLjt, and VLDL triglycerides correlated highly significantly as well.
The Figure shows the regression curves and the corresponding equations for the concentrations of VLDL triglycerides, HDLa, and HDLj,, on PAI-1 activity. The HDL^ concentration was highly significantly positively correlated to the PAI-1 activity (R 2 =.38, P<.001) for both patients and control subjects (i? 2 =.47 and .31, respectively; both P<.00l). The HDLa, level was significantly and inversely correlated to the PAI-1 activity (R 2 =.23,P<.01) in patients and control subjects (both R 2 =.21; P<.05 and P<.01, respectively). The correlation between VLDL triglyceride levels and PAI-1 activity became significant after removal of one outlier with a VLDL triglyceride concentration above 7 mmol/L (R 2 =.16, P<.05). This correlation was limited to the patient group and was not found in the control group (R 2 =.22, P<.05 and R 2 =.O7, NS, respectively).
Discussion
The genesis of atherosclerosis is multifactorial, 27 and intermittent ciaudication, which is usually associated with pronounced atherosclerosis, is a late symptom of that process. It is thus not surprising that subjects with established intermittent ciaudication also frequently have other manifestations of atherosclerosis and concomitant treatment for these diseases. The subjects in the patient group who were being treated with /3-blockers (selective or unselective) or thiazides predictably had a greater incidence of CHD (angina pectoris, a previous myocardial infarction, or bypass surgery) and hypertension compared with the patients not treated with these agents. Differences between these two groups may thus be ascribed either to the more severe disease of the patients on medication, the /J-blocker/ thiazide treatment itself, or to both factors. This cannot directly be solved by a case-control study like ours. However, the results of the multiple regression analysis for presence of intermittent ciaudication was basically the same regardless of whether the patients treated with j3-blockers/thiazides were included. This suggests that the results are related to the disease and that they are not secondary to treatment.
The new findings of the present study were that normoglucemic intermittent ciaudication patients, when compared with age-, sex-, BMI-, and smoking habitmatched controls, had (1) lower levels of large HDL particle size subclasses, ie, HDLa, HDL^, and HDL3,; (2) higher PAI-1 activity; and (3) a highly significant positive correlation between PAI-1 and the concentration of HDL^. Finally, (4) the Lp(a) concentration, which was elevated in patients compared with control subjects, correlated significantly to activation of the coagulation system (plasma fibrinogen and urine fibrinopeptide) but not to variables describing fibrinolytic capacity (PAI-1 and plasma a 2 -antiplasmin).
The protein concentrations of the particle size-defined HDL subclasses H D L a , HDLj,, and HDLj, were significantly lower in the patient group. The intermittent claudication patients not taking 0-blockers/thiazides had only a lowered HDL^ value. The apolipoprotein composition of various HDL subclasses may influence the capacity of reverse cholesterol transport and atherosclerosis development. 28 ' 29 Subclasses HDLa, and HDL3, contain lipoprotein particles with apolipoprotein (apo) A-I without apo A-II (LpA-I), whereas lipoprotein particles with both apo A-I and apo A-II are distributed along the entire HDL particle size range. 30 The so-called atheroprotective effect associated with H D L a that was previously shown for CHD 8 -9 or the similar protective effect found in the present study for H D L a and HDLj, particles for intermittent claudication may thus be ascribed to their LpA-I content. 29 -30 Furthermore, the capacity of different HDL subclasses to scavenge free radicals, thereby protecting cell and lipid structures from oxidative modifications, might vary.
-32
The Lp(a) levels of the patients were significantly higher than those of the control subjects, a finding that confirms the results of two recent studies.
33
- 34 A link between Lp(a) and the fibrinorytic system has been considered likely because of the high degree of homology between apo(a), the glycoprotein of Lp(a), and plasminogen. No correlations were found, however, between Lp(a) and the fibrinolytic index variables PAI-1 and plasma a 2 -antiplasmin. To our surprise, the Lp(a) levels correlated positively to an activation of the coagulation system, ie, to the plasma fibrinogen and urine fibrinopeptide A concentrations. The positive correlation between the values for Lp(a) and plasma fibrinogen was found for patients but not for control subjects, suggesting that the presence of widespread atherosclerosis may influence this relation. Further studies are needed to discern the pathophysiological relevance of these findings.
Elevated plasma fibrinogen has been demonstrated in case-control studies on patients with intermittent claudication 10 and prospectively for CHD. 35 -36 In our study the levels of plasma fibrinogen were also elevated in the intermittent claudication group. Fibrin formation is essential for fibroblasts and other cells to invade a lesioned area. A study by Fatah et al 37 shows that patients with coronary atherosclerosis have an increased density of the fibrin network, which might increase the resistance of fibrin to plasmic degradation. PAI-1 has an essential role in fibrinolysis. 38 The original finding of elevated PAI-1 levels in peripheral atherosclerosis disease in the present study agrees with studies on CHD that show increased PAI-1 levels in postmyocardial infarction patients.
11 - 39 The highly significant positive correlation between PAI-1 activity and HDLH, was found for both patients and control subjects. Since the HDI^, levels did not differ between the patient and control groups, whereas the PAI-1 activity did, it follows that the intermittent claudication patients, for a given HOLfe concentration, had a higher PAI-1 activity than the sex-, age-, BMI-, and smoking habit-matched control subjects. Whether HDL^ particles exert direct effects on PAI-1-producing endothelial cells and/or hepatic cells needs to be clarified. A high level of HDI^b has been shown to be associated with elevated values of several risk factors for CHD, including triglycerides and small, dense LDL particles. 40 - 41 Thus, it cannot be excluded that the correlation between HDL3,, and PAI-1 activity may be mediated by some of these CHD risk factors.
In conclusion, subjects with intermittent claudication have increased coagulation activity and inhibited fibrinolysis as well as a lower concentration of large HDL particles and increased Lp(a) levels. Several strong associations found between hemostasis and lipoprotein metabolism for both patients with intermittent claudi- PAI-1 indicates plasminogen activator inhibitor-1; VLDL-TG, very-low-density lipoprotein triglycerides; HDL, high-density lipoprotein. Univariate correlation coefficients were obtained by using the Spearman rank test. In the partial correlation the relationship between two variables was calculated while the covariating effects by the other included variables were controlled. For control subjects, n=33 and for patients, n=24.
* cation and "healthy" control subjects need to be delineated in prospective and experimental studies.
